Abstract 2031: Supramolecularly Fabricated Non-thrombogenic Small Diameter Vascular Graft

Le résumé fourni par la source

Background: Small diameter (<6mm) arterial reconstruction often requires the use of autologous and synthetic vascular substitutes. While autologous conduits are the gold standard, because of their limited availability synthetic conduits are often used. However, synthetic conduits can lead to poor outcomes due to thrombosis and lumen occlusion occluding the lumen and result in graft failure. By modulating the biopolymer properties of the synthetic conduits, graft failure can be prevented. In this study, we present a thromboresistant synthetic vascular graft (zetagraft) fabricated with tunable biopolymers for small diameter arterial reconstructions. Methods: Zetagrafts were fabricated by the solvent extraction driven self-assembly using a concentric tubular assembly device using polyvinyl alcohol dissolved in dimethyl sulfoxide (15% w/v). We characterized the physicochemical and mechanical properties of zetagraft by fourier transform infrared spectroscopy (FTIR), X-ray diffraction analysis (XRD), optical and scanning electron microscopy, and tensiometry. In-vitro studies were performed on the zetagraft using fibroblast, HUVEC and MVEC cell lines. Ex vivo hemocompatibility analysis was performed with fresh porcine blood. The zetagrafts were implanted in a rat aorta replacement model to evaluate its thromboresistance. Results: The zetagraft was uniform, highly stretchable, and self-healing when punctured with a needle. Blood circulation followed by FT-IR and XRD analysis showed no protein adsorption on the luminal surface. Immuno fluorescence staining revealed the absence of platelet and blood cell adsorption on the zetagraft lumen, demonstrating its thromboresistance. In vivo implantation of the zetagraft in rat abdominal aorta replacement model revealed the absence of thrombosis and other blood component adsorption on the zetagraft lumen. Conclusions: Advances in material science allow for fabrication of more tunable biocompatible small vascular grafts. In this study we demonstrated the development of a thromboresistant zetagraft. Our early results are very promising and zetagraft will provide a novel small vascular graft and thus fulfil an important unmet clinical need.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.